Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
Initiation of Phase I clinical study of first needle-free COVID-19 vaccine
9 Nov 2022
Latest
-
-
UQ professor pedals for purpose
15 April 2024 -
Saving Queensland’s earless dragons
12 April 2024
